| Document And Entity Information | Nov. 07, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Nov. 07, 2022 |
| Entity Registrant Name | Verve Therapeutics, Inc. |
| Entity Central Index Key | 0001840574 |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Entity File Number | 001-40489 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 82-4800132 |
| Entity Address, Address Line One | 201 Brookline Avenue, Suite 601 |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02215 |
| City Area Code | (617) |
| Local Phone Number | 603-0070 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, $0.001 par value per share |
| Trading Symbol | VERV |
| Security Exchange Name | NASDAQ |
